您当前所在的位置:首页 > 产品中心 > 产品信息
Doxacurium chloride_分子结构_CAS_106819-53-8)
点击图片或这里关闭

Doxacurium chloride

产品号 DB01135 公司名称 DrugBank
CAS号 106819-53-8 公司网站 http://www.ualberta.ca/
分子式 C56H78N2O16++ 电 话 (780) 492-3111
分子量 1035.22232 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 1006

产品价格信息

请登录

产品别名

标题
Doxacurium chloride
IUPAC标准名
6,7,8-trimethoxy-2-methyl-2-(3-{[4-oxo-4-(3-{6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propoxy)butanoyl]oxy}propyl)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium
IUPAC传统名
doxacurii chloridum
商标名
Nuromax

产品登记号

PubChem SID 46506733
PubChem CID 60169
CAS号 106819-53-8

产品性质

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.
Indication Used to provide skeletal muscle relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical ventilation.
Pharmacology Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant. The neuromuscular block produced by doxacurium chloride may be antagonized by anticholinesterase agents. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at reversal, the longer the time and the greater the dose of anticholinesterase required for recovery of neuromuscular function. Doxacurium chloride is approximately 2.5 to 3 times more potent than pancuronium and 10 to 12 times more potent than metocurine.
Toxicity Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
Affected Organisms
Humans and other mammals
Biotransformation In vivo data from humans suggest that doxacurium chloride is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.
Half Life 99 minutes in normal healthy adults.
Protein Binding Approximately 30%.
Elimination In vivo data from humans suggest that NUROMAX is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.
Distribution * 0.11-0.43 L/kg [Healthy Young Adult Patients]
* 0.17-0.55 L/kg [Kidney Transplant Patients]
* 0.17-0.35 L/kg [Liver Transplant Patients]
Clearance * 2.66 mL/min/kg [Healthy Young Adult Patients]
* 1.23 mL/min/kg [Kidney Transplant Patients]
* 2.3 mL/min/kg [Liver Transplant Patients]
* 1.75 +/- 0.16 mL/min/kg [Elderly patients (70-83 yrs)]
* 2.54 +/- 0.24 mL/min/kg [younger patients (19-39 yrs)]
References
Martinez EA, Wooldridge AA, Hartsfield SM, Mealey KL: Neuromuscular effects of doxacurium chloride in isoflurane-anesthetized dogs. Vet Surg. 1998 May-Jun;27(3):279-83. [Pubmed]
External Links
Wikipedia
RxList

参考文献

  • Martinez EA, Wooldridge AA, Hartsfield SM, Mealey KL: Neuromuscular effects of doxacurium chloride in isoflurane-anesthetized dogs. Vet Surg. 1998 May-Jun;27(3):279-83. Pubmed